PCA
LAB icon

Pallas Capital Advisors’s Standard BioTools LAB Stock Holding History

Pallas Capital Advisors’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-10,576
Closed -$13.7K – 917
2025
Q3 		$13.7K Buy
10,576
+291
+3% +$381 ﹤0.01% 871
2025
Q2 		$12.3K Sell
10,285
-2,067
-17% -$2.29K ﹤0.01% 854
2025
Q1 		$13.3K Buy
+12,352
New +$17.3K ﹤0.01% 758

Other funds holding LAB

CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MCO
MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
HBWM
Hollow Brook Wealth Management Katonah, New York $392M AUM 36.68% 1-Year Est. Return

Pallas Capital Advisors's LAB Position: Q4 2025 in Review

Pallas Capital Advisors sold out of Standard BioTools (LAB) in Q4 2025, closing a stake of 10,576 shares — an estimated $13.7K sold.

Pallas Capital Advisors first reported a position in LAB in Q1 2025 and held it in 3 quarters. The position peaked at $13.7K in Q3 2025. 159 funds tracked by Wall St. Rank hold LAB as of Q4 2025.

  • Pallas Capital Advisors reported no remaining Standard BioTools position as of Q4 2025 after selling out during the quarter.
  • Pallas Capital Advisors sold 10,576 Standard BioTools shares in Q4 2025, an estimated $13.7K.
  • Pallas Capital Advisors first reported a position in Standard BioTools in Q1 2025 and held it in 3 quarters.
  • Pallas Capital Advisors's Standard BioTools position peaked at $13.7K in Q3 2025.
  • 159 funds tracked by Wall St. Rank held Standard BioTools as of Q4 2025.

Based on Pallas Capital Advisors's 13F filing for Q4 2025, filed 14 Jan 2026.